MDACC Study No:2012-0171 ( NCT No: NCT01539512)
Title:A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and
Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic
Principal Investigator:William G. Wierda
Treatment Agent:GS-1101
Study Status:Closed
Study Description:The goal of this clinical research study is to find out if adding idelalisib to
treatment with rituximab is more effective in controlling CLL than treatment
with rituximab alone. The safety of this drug combination will also be

Rituximab is designed to attach to cancer cells and damage them, which may
cause the cells to die.

Idelalisib is designed to block some of the cell functions that cause CLL cells
to grow and survive.

A placebo is not a drug. It looks like the study drug but is not designed to
treat any disease or illness. It is designed to be compared with a study drug
to learn if the study drug has any real effect.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase III
Treatment Agents:GS-1101
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Gilead Sciences
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:William G. Wierda
For Clinical Trial Enrollment:713-792-7543
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults